



2019 Annual Report and Notice of Annual General Meeting April 22nd, 2020

Oslo, April 15, 2020 – Vaccibody announces that the Board has approved the Annual report 2019, and calls for The Annual General Meeting to be held at the Company's offices at Forskningsparken, on 22 April 2020 at 13:00 CET (meeting room "Hagen 4").

The 2019 Annual Report and all documents regarding the Annual General Meeting are attached to this release. The notice will be sent to all registered shareholders and is also available at the Company's website: www.vaccibody.com

As a consequence of the extraordinary situation related to the corona virus the Company encourages shareholders not to attend the general meeting in person, but rather to make use of the ability to vote by proxy.

The Annual General Meeting will be conducted as briefly as possible, and representation of Vaccibody's Board of Directors and administration will be kept to a minimum.

Notice of attendance

Notice of attendance must be received no later than 21 April 2020 at 16:00 CET. Submission of proxies must be received no later than 21 April 2020 at 16:00 CET. The notice and appendices will also be made available on Vaccibody's website, www.vaccibody.com

About Vaccibody

Vaccibody is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies. The Company is a leader in the rapidly developing field of individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate best-in-class therapeutics to treat cancers with a high unmet medical need. Further, the Company focuses its research on infectious diseases.

Vaccibody is developing cutting-edge, targeted DNA vaccines for clinical use, based on a deep understanding of immunological principles. Vaccibody's vaccines specifically target Antigen Presenting Cells (APC), which are essential for inducing rapid, strong and specific immune responses and elicit efficacious clinical responses. By intelligent design, Vaccibody's vaccines can be tailored to induce the desired immune response profile correlating with protection for each specific disease with any given antigen. Hence, the Vaccibody vaccine platform has the potential to address many disease areas with a high unmet medical need such as cancer and infectious diseases. In addition, Vaccibody has collaborations with Roche and Nektar Therapeutics.

Vaccibody's lead product candidates are VB10.NEO, a personalized therapeutic cancer neoantigen vaccine currently being evaluated in a Phase I/IIa clinical trial, and VB10.16, a therapeutic cancer vaccine against HPV16-related cancers that is currently being tested in a Phase II clinical trial.

Vaccibody's shares are traded on NOTC, a marketplace for unlisted shares managed by NOTC AS, which is owned 100% by Oslo Børs ASA, the Oslo Stock Exchange.

Further information about the Company may be found at <http://www.vaccibody.com>

Contact:

CEO Michael Engsig
Vaccibody AS
Cell: +45 6173 1509
mengsig@vaccibody.com

Vaccibody AS

Oslo Research Park
Gaustadalléen 21
0349 Oslo, Norway